In vitro studies of two triazole antifungal agents (voriconazole [UK- 109,496] and fluconazole) against Candida species

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1948-1949

  Barry, Arthur L ^a   Brown, Steven D ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; DRUG POTENCY; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029799501     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1948     Document Type: Article

References (10)

1. Barchiesi, F., M. Restrepo, D. A. McGough, and M. G. Rinaldi. 1995. In vitro activity of a new antifungal triazole: UK-109,496, abstr F71, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Denning, D., A. del Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Dupont, B., D. Denning, H. Lode, S. Yonren, P. Troke, and N. Sarantris. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis, abstr. F81, p. 127. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. McGinnis, M. R., L. Pasarell, and C. R. Cooper, Jr. 1995. In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole, abstr. E76, p. 99. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
7. Patterson, B. E., and P. E. Coates. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for treatment of fungal infections: pharmacokinetics in man, abstr. F78, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Richardson, K., A. S. Bell, R. P. Dickinson, S. Narayanaswami, and S. J. Ray. 1995. UK-109,496, a novel, wide-spectrum derivative for the treatment of fungal infections: synthesis and SAR, abstr. F69, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Troke, P. F., A. S. Bell, R. P. Dickinson, C. A. Hitchcock, S. Jezequel, S. Narayanaswami, S. J. Ray, and K. Richardson. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for treatment of systemic fungal infections: discovery and antifungal properties, abstr. F70, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Troke, P. F., K. W. Brammer, C. A. Hitchcock, S. Youren, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC), abstr. F73, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.